Bookmark

Add to MyYahoo RSS

CGI Pharmaceuticals News

News on CGI Pharmaceuticals (Ticker: GILD) continually updated from thousands of sources around the net.

Friday Aug 29 | Seeking Alpha

Today's Market: Red Hot Biotech And Big Pharma Names To Watch

A busy week is about to come to an end, but not before we have learned a lot about the strength of this market and just how resilient it is.

Comment?

Related Topix: Biotech, Science / Technology, Medicine, Amgen, Healthcare Industry, Startups, Gilead Sciences

Thu Aug 28, 2014

Seeking Alpha

When Will M&A Come To The Hepatitis C Space?

Biotech InterMune was taken out by Roche for over $8 billion yesterday in a deal that had an almost 40% buyout premium.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, InterMune, Healthcare Industry, Gilead Sciences, Startups, Achillion Pharmaceuticals

Wed Aug 27, 2014

Seeking Alpha

Gilead Sciences: Due For More Short Squeezing?

Short sellers of Gilead Sciences must be starting to sweat a bit as the stock continues its impressive trajectory: However, the short interest figures just came out for the first half of August and they in fact show that about 8 million shares were covered in that time period.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

Tue Aug 26, 2014

Barron's

Biotech Stocks: Time to Worry

I mean, just look at these returns: Gilead Sciences has gained 41% so far this year as investors appear to have put their Sovaldi worries behind them ; InterMune has quintupled in 2014 after Roche agreed to purchase it for $8.3 billion ; and Intercept Pharmaceuticals has surged 350% as drug trials have been surprisingly good .

Comment?

Related Topix: Biotech, Science / Technology, Financial Markets, Medicine, Gilead Sciences, Healthcare Industry, Startups, InterMune

Seeking Alpha

Gilead Sciences: Despite This Year's Triumphs, Watch Out For Weaknesses - An Algorithmic Perspective

Gilead Sciences, a pharmaceuticals company specializing in drug discovery, development, and commercialization, has seen considerable success recently: its strong first- and second-quarter results make its 2014 analyst rating primarily bullish.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Science, Computer Science, Hepatitis, Health, San Mateo County, CA, Foster City, CA

Mon Aug 25, 2014

Reuters

Us Stocks-S&P 500 tops 2,000 for first time in broad advance

The S&P 500 stock index rose to an intraday record on Monday, topping 2,000 for the first time in a broad rally led by financial and biotechnology stocks.

Comment?

Related Topix: Financial Markets, Biotech, Science / Technology, InterMune, Medicine, Healthcare Industry, Startups, Gilead Sciences, Annapolis, MD

Sat Aug 23, 2014

AmericanBankingNews.com

RBC Capital Increases Gilead Sciences Price Target to $115.00

The firm currently has an "outperform" rating on the stock. RBC Capital's price target points to a potential upside of 10.62% from the company's current price.

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, Healthcare Industry

Thu Aug 21, 2014

TheStreet.com

Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Mozilla, TheStreetcom, Media, TheStreet, Computers

Wed Aug 20, 2014

AmericanBankingNews.com

Recent Analysts' Ratings Updates for Gilead Sciences

A number of stock research firms have changed their ratings and price targets for Gilead Sciences during the last seven days: Gilead Sciences is now covered by analysts at Argus.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

Fri Aug 15, 2014

Seeking Alpha

Gilead: Rising Short Interest Provides Yet Another Reason To Own The Stock

Its forward P/E is low relative to the market, thus incorporating caution about the sustainability of profits from its hepatitis C franchise.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Pharmaceuticals, Pharmasset

Silicon Alley Insider

Biotech Stock Achillion Is Soaring After Good News About Its Hepatitis C Drug

Achillion Pharmaceuticals was up more than 11% on Friday after the company announced positive interim results for its hepatitis C treatment.

Comment?

Related Topix: Achillion Pharmaceuticals, Pharmaceuticals, Healthcare Law, Law, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

Seeking Alpha

Gilead: More Good News For This Biotech Juggernaut

Highlighted below is my rebuttal to a recent short thesis on Gilead and why is stock is still cheap and going much higher.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

Tue Aug 12, 2014

Seeking Alpha

Cramer's Lightning Round - El Pollo Loco Is Acting Crazy

StoneMor Partners : "I don't understand why it yields 10%. That would usually be a red flag, but I like StoneMor."

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, Healthcare Industry

Wed Aug 06, 2014

AmericanBankingNews.com

Zacks Downgrades Gilead Sciences to Neutral

They currently have a $97.00 target price on the stock. Zacks 's price objective suggests a potential upside of 5.13% from the stock's previous close.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

Mon Aug 04, 2014

Seattle Post-Intelligencer

Blue Shield of California CEO: Hepatitis C pill shows drug pricing is 'broken'

The head of Blue Shield of California on Monday said Gilead Sciences' controversial hepatitis C drug is unsustainable at $1,000 a day, joining a growing chorus of payers who are unhappy with the price.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups

Seeking Alpha

Why Gilead Sciences Stock Is Still A Great Investment Opportunity

Gilead has compelling valuation metrics and exceptional earnings growth prospects; its PEG ratio of 0.41, is the lowest among all S&P 500 companies.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Hepatitis, Health, Financial Markets, San Mateo County, CA, Foster City, CA

Sun Aug 03, 2014

SFGate

New FDA process speeds approval of high-priced breakthrough drugs

This undated file handout photo provided by Gilead Sciences shows the hepatitis C medication Sovaldi.

Comment?

Related Topix: Healthcare Law, Law, Food and Drug Administration, Biotech, Medicine, Gilead Sciences, Healthcare Industry, Startups, Hepatitis, Health

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••